Navigation Links
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Date:12/2/2008

SKOKIE, Ill., Dec. 2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints. HZT-501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (gastric and/or duodenal) ulcers in patients with mild-to-moderate pain when compared to ibuprofen alone.

NSAIDs such as ibuprofen are among the most widely used drugs in the world. However, NSAIDs are associated with a range of adverse side effects, which primarily affect the gastrointestinal (GI) tract. Up to 30 percent of patients taking NSAIDs experience gastrointestinal ulcers and a greater percent suffer from upper GI symptoms (i.e., dyspepsia, heartburn).

"NSAIDs, while highly effective in treating pain and inflammation, often lead to serious safety concerns, including significant gastrointestinal damage," said Timothy P. Walbert, president and chief executive officer, Horizon Therapeutics. "We are committed to bringing this much needed treatment to physicians and patients as quickly as possible and plan on submitting these strong HZT-501 Phase 3 results to U.S. and European regulatory authorities in 2009."

REDUCE-1 and REDUCE-2 Trial Design and Results

The Registration Endoscopic Study to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Study (REDUCE-1 and REDUCE-2) were two randomized, double-blind, controlled trials that enrolled more than 1,500 patients in the United States. The primary efficacy objective of REDUCE-1 was to evaluate HZT-501 in reducing the proportion of patients who develop endoscopically diagnosed gastric ulcers during the 24-week treatment pe
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
2. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
5. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
6. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
11. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... of fiscal year 2014 financial results after the market ... call will follow on the same day at 4:30 ... be hosted by Dan Myers , President and ...
(Date:7/24/2014)... KIRKLAND, Wash. , July 24, 2014 ... exhibiting at the 2014 National Association of State Veterans ... Carolina . The goal of the NASVH is ... receives the benefits, services, long term health care and ... sacrifice. With the InSite® Remote Dispensing ...
(Date:7/24/2014)... 2014 Consolidated Net Profit increased by 43.65 ...   , India Business grew by 20.87% to Rs. ... 4,886.70 Mn Rest of World (ROW) Business grew by ... by 34.53% to Rs. 977.26 Mn Latin America Business ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4
... Inc. (OTC Bulletin Board: HEWA), a ... a wholly-owned subsidiary of Huntington Bancshares Incorporated (Nasdaq: ... announced today a partnership that will give customers across ... HealthWarehouse.com will be added to the prescription ...
... 2011 On Wednesday, February 16, 2011, at ... members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq and ... call to discuss the Company,s 2010 fourth quarter ... February 168:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. ...
Cached Medicine Technology:HealthWarehouse.com and Huntington Insurance Partner to Help Self-Insured Employers in the Midwest Save on Prescription Medications 2
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... at night, which shuts off nighttime production of the ... a widely used breast cancer drug, says a new ... The study, "Circadian and Melatonin Disruption by Exposure to ... in Breast Cancer," published in the journal Cancer ... is vital to the success of tamoxifen in treating ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay News) ... wrong, according to a small study that asked boys what they ... between the ages of 14 and 16, researchers found that most ... and trust. Very few boasted about sexual conquests or saw sex ... "In our culture, we have lots of assumptions about how ...
(Date:7/24/2014)... Pools and beaches are the place to ... dangerous, especially for small children, so Amica Insurance ... to the Centers for Disease Control and Prevention, children between ... for water-related injuries and deaths. It’s important to know the ... Amica is offering the following tips from the American Red ...
Breaking Medicine News(10 mins):Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... suggests ways for FDA to beef up its oversight, , ... misled by the health claims made on the packaging of ... Institute of Medicine, because those claims do not undergo the ... A box of cereal that proclaims the breakfast food will ...
... ... with massage therapy , ... Scottsdale, AZ (PRWEB) May 12, 2010 -- Fibromyalgia has quickly gone from being ... conditions in American medicine. New treatments, medications and preventions are being developed every year ...
... ... with International Medical Group® (IMG®) to serve overseas missionaries. Each year Good ... focus is caring and honest service. IMG serves the needy in our ... mission sending organizations. Good Neighbor Insurance and IMG are particularly proud of ...
... disagree whether behavior describes a true addict , WEDNESDAY, May ... real problem in some people, causing them to engage in ... , The career of professional golfer Tiger Woods took a ... dozen women. Former New York Mets general manager Steve Phillips ...
... ... video conferencing solutions , ... Buffalo, NY (PRWEB) May 12, 2010 -- VoIP Supply, LLC North America’s leading ... introduction of video conferencing solutions to its base of over 75,000 customers. The initial ...
... “Choose ... ... -- Addressing the country’s obesity crisis, President Obama has declared May to be National ... attention to this complex problem. President Obama, in his proclamation, is asking ...
Cached Medicine News:Health News:Health Claims on Foods May Not Be Well-Grounded 2Health News:Health Claims on Foods May Not Be Well-Grounded 3Health News:Massage Envy Offers Relief for Fibromyalgia Sufferers 2Health News:Massage Envy Offers Relief for Fibromyalgia Sufferers 3Health News:Serving the World With Specialized Insurance for Missionaries 2Health News:Serving the World With Specialized Insurance for Missionaries 3Health News:Serving the World With Specialized Insurance for Missionaries 4Health News:The 'Reality' of Sex Addiction Stirs Debate 2Health News:The 'Reality' of Sex Addiction Stirs Debate 3Health News:VoIP Supply Launches Video Conferencing Solutions 2Health News:Dealtaker.com Shows Support for White House National Health and Fitness Initiatives 2
This stain is the McNeal formula and can be substituted for Wright Stain solution....
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Medicine Products: